<DOC>
	<DOCNO>NCT01444339</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , immunogenicity two investigational pneumococcal vaccine three dose level healthy adult . Primary Objective : - To evaluate safety tolerability two investigational pneumococcal vaccine . Observational Objective : - To evaluate immunogenicity investigational pneumococcal vaccine .</brief_summary>
	<brief_title>Study Two Investigational Pneumococcal Vaccines Healthy Adults</brief_title>
	<detailed_description>An initial cohort 6 participant receive single dose one two investigational pneumococcal vaccine . After safety evaluation cohort , additional cohort receive 2 injection 30 day apart investigational pneumococcal vaccine increase dose level . All participant monitor safety 30 day vaccination .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 18 50 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure Subject healthy , determined medical history physical examination For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination 4 week last vaccination . Known pregnancy positive serum/urine pregnancy test Currently breastfeed child Chronic illness , opinion investigator , stage could interfere trial conduct completion Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known systemic hypersensitivity vaccine component history life threaten reaction trial vaccine ( ) vaccine contain substance Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine 4 week follow trial vaccination Known seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C Laboratory confirm / selfreported thrombocytopenia contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Identified study site employee involve protocol may direct access trialrelated data Previous vaccination pneumococcal disease ( previous 5 year ) History pneumococcal infection ( confirm either clinically , serologically , microbiologically ) within 5 year At high risk pneumococcal infection trial Living household child &lt; 5 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Pneumococcal Infections</keyword>
	<keyword>Streptococcus Pneumoniae Infections</keyword>
	<keyword>Pneumococcal Vaccine</keyword>
</DOC>